Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma

Background: Checkpoint inhibitors, such as PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab), are widely used in metastatic melanoma, and most immune-related adverse events are known. Several cardiovascular AEs (CVAEs) associated with immune checkpoint inhibitor exposur...

Full description

Bibliographic Details
Main Authors: Jean-Matthieu L’Orphelin, Charles Dollalille, Julia Akroun, Joachim Alexandre, Anne Dompmartin
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
melanoma
adverse events
immunotherapy
cardiology
CVAE
Online Access:https://www.mdpi.com/2072-6694/15/7/2170

Internet

https://www.mdpi.com/2072-6694/15/7/2170

Similar Items